<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02169804</url>
  </required_header>
  <id_info>
    <org_study_id>ZA-111</org_study_id>
    <nct_id>NCT02169804</nct_id>
  </id_info>
  <brief_title>An Open-Label Study to Evaluate the Effect of Age Upon the Pharmacokinetics of Androxal</brief_title>
  <official_title>An Open-Label Study to Evaluate the Effect of Age Upon the Pharmacokinetics of Androxal</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Repros Therapeutics Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Repros Therapeutics Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      • To determine and compare the pharmacokinetics (PK) of 3 doses of 25 mg Androxal in elderly
      healthy adult male subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2014</start_date>
  <completion_date type="Actual">August 2014</completion_date>
  <primary_completion_date type="Actual">August 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics - The Cmax will be calculated.</measure>
    <time_frame>4 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics - The Tmax will be calculated.</measure>
    <time_frame>4 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics - The AUC0-24 will be calculated.</measure>
    <time_frame>4 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics - the AUC0-∞ will be calculated.</measure>
    <time_frame>4 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics - The t½ will be calculated.</measure>
    <time_frame>4 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety - Incidence of adverse events</measure>
    <time_frame>4 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety -Mean change from baseline in laboratory values</measure>
    <time_frame>4 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety - Mean change from baseline in vital signs</measure>
    <time_frame>4 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Pharmacokinetics</condition>
  <arm_group>
    <arm_group_label>70 years or older</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Non-smoking healthy adult males &gt;or equal to 70 years of age.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Under 60 years of age</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Non-smoking healthy adult males&lt;60 years of age.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Androxal 25 mg</intervention_name>
    <arm_group_label>70 years or older</arm_group_label>
    <arm_group_label>Under 60 years of age</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Speak, read, and understand English or Spanish and is willing and able to provide
             written informed consent on an IRB-approved form prior to the initiation of any study
             procedures;

          2. Male; age &lt;60 or ≥70 years of age

          3. No significant abnormal findings at the screening physical examination as evaluated by
             the Investigator;

          4. Normal laboratory values (or abnormal but not clinically significant) at screening as
             determined by the Investigator;

          5. Subject is willing to remain in the clinic for the screening visit and one overnight
             treatment visit after the 3rd dose of Androxal (approximately 36 hours for the
             treatment visit)

          6. Must be able to swallow gelatin capsules

        Exclusion Criteria:

          1. Known hypersensitivity to Clomid;

          2. Abnormal screening visit vital signs or clinical laboratory evaluation considered
             clinically significant by the Investigator;

          3. A hematocrit &gt;54% or a hemoglobin &gt;17 g/dL.

          4. Subject with a significant organ abnormality or disease as determined by the
             Investigator;

          5. Any medical condition that would interfere with the study as determined by the
             Investigator;

          6. Participation in a clinical trial with investigational medication within 30 days prior
             to study medication administration;

          7. An acute illness within 5 days of study medication administration;

          8. Positive urine drug screen at the screening visit;

          9. Known history of HIV and/or Hepatitis B or C

         10. Tobacco (nicotine products) use in the 3 months prior to the study;

         11. A mental condition rendering the subject unable to understand the nature, scope, and
             possible consequences of the study and/or evidence of an uncooperative attitude, as
             determined by the Investigator;

         12. History of venous thromboembolic disease (e.g. deep vein thrombosis or pulmonary
             embolism);

         13. History of myocardial infarction, unstable angina, symptomatic heart failure,
             ventricular dysrhythmia, or known history of QTc interval prolongation;

         14. An employee or family member of an employee of the study site or the Sponsor;

         15. Previous participation in a clinical study of Androxal.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 16, 2014</study_first_submitted>
  <study_first_submitted_qc>June 19, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 23, 2014</study_first_posted>
  <last_update_submitted>September 29, 2014</last_update_submitted>
  <last_update_submitted_qc>September 29, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 1, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Enclomiphene</mesh_term>
    <mesh_term>Clomiphene</mesh_term>
    <mesh_term>Zuclomiphene</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

